CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia‑induced damage

Liu,Guanghui; Zhao,Hongchao; Ding,Qingqing; Li,Haohao; Liu,Tao; Yang,Hongwei; Liu,Yuanhua

doi:10.3892/mmr.2021.11879

CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia‑induced damage

Authors:
- Guanghui Liu
- Hongchao Zhao
- Qingqing Ding
- Haohao Li
- Tao Liu
- Hongwei Yang
- Yuanhua Liu
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China
Published online on: January 28, 2021 https://doi.org/10.3892/mmr.2021.11879
Article Number: 240
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hyperthermia is one of the most widely employed adjuvant treatments for cancer, especially for hyperthermic intraperitoneal chemotherapy, and has few side effects. Gastric cancer has various hyperthermia sensitivities, but the exact molecular mechanisms remain to be elucidated. In the present study, western blotting was performed to detect differential expression of proteins that have been reported to be upregulated in gastric cancer. Following knockdown of these proteins, apoptosis was measured by Annexin V‑FITC/propidium iodide (PI) double staining and hyperthermia treatment was applied. To evaluate the effect of cyclin‑dependent kinase 6 (CDK6) on hyperthermia‑induced apoptosis, CDK6 was knocked down or inhibited by the addition of a specific inhibitor and subsequent PI staining and cell proliferation, migration and invasion assays were performed. Hyperthermia‑induced protein kinase B (AKT) expression and phosphorylation inhibition were detected. As demonstrated in the present study, the hyperthermia‑induced proteins kinesin family member 11 (KIF11), cyclin‑dependent kinase 6 (CDK6), stromal antigen 2, NIMA‑related kinase 2 and karyopherin subunit α 4 were highly expressed in gastric cancer cells, including SH‑10‑TC and HGC‑27 cells. Knockdown of KIF11 significantly increased apoptosis without hyperthermia treatment and CDK6 significantly increased hyperthermia‑induced apoptosis, prompting the present study to focus on CDK6. It was further confirmed that CDK6 activity was critical for decreasing hyperthermia‑induced apoptosis and for cell proliferation. Hyperthermia‑induced AKT expression and phosphorylation inhibition is potentially the main cause of CDK6 transcriptional upregulation. Taken together, these findings demonstrated that CDK6 is upregulated via hyperthermia‑induced AKT inhibition and subsequently protected gastric cancer cells from hyperthermia‑induced apoptosis, indicating that it is a potential therapeutic target to sensitize gastric cancer cells to hyperthermia‑based therapy.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Siegel RL, Ward EM and Jemal A: Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
3	Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE and de Hingh IH: Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer. 134:622–628. 2014. View Article : Google Scholar : PubMed/NCBI
4	Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
5	D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M and Karpeh MS: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 240:808–816. 2004. View Article : Google Scholar : PubMed/NCBI
6	Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
7	Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
8	Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, et al: Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 30:2327–2333. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, Königsrainer I, Königsrainer A, Beckert S and Löffler MW: Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med. 7:5672018. View Article : Google Scholar
10	Tao Y, Guo Y, Liu W, Zhang J, Li X, Shen L, Ru Y, Xue Y, Zheng J, Liu X, et al: AKT inhibitor suppresses hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells. Braz J Med Biol Res. 46:394–404. 2013. View Article : Google Scholar : PubMed/NCBI
11	Habash RW, Bansal R, Krewski D and Alhafid HT: Thermal therapy, part 2: Hyperthermia techniques. Crit Rev Biomed Eng. 34:491–542. 2006. View Article : Google Scholar : PubMed/NCBI
12	Habash RW, Bansal R, Krewski D and Alhafid HT: Thermal therapy, part 1: An introduction to thermal therapy. Crit Rev Biomed Eng. 34:459–489. 2006. View Article : Google Scholar : PubMed/NCBI
13	Roti RJ: Cellular responses to hyperthermia (40–46 degrees C): Cell killing and molecular events. Int J Hyperthermia. 24:3–15. 2008. View Article : Google Scholar : PubMed/NCBI
14	Koutcher JA, Barnett D, Kornblith AB, Cowburn D, Brady TJ and Gerweck LE: Relationship of changes in pH and energy status to hypoxic cell fraction and hyperthermia sensitivity. Int J Radiat Oncol Biol Phys. 18:1429–1435. 1990. View Article : Google Scholar : PubMed/NCBI
15	Tabuchi Y, Wada S, Furusawa Y, Ohtsuka K and Kondo T: Gene networks related to the cell death elicited by hyperthermia in human oral squamous cell carcinoma HSC-3 cells. Int J Mol Med. 29:380–386. 2012.PubMed/NCBI
16	Tabuchi Y, Takasaki I, Wada S, Zhao QL, Hori T, Nomura T, Ohtsuka K and Kondo T: Genes and genetic networks responsive to mild hyperthermia in human lymphoma U937 cells. Int J Hyperthermia. 24:613–622. 2008. View Article : Google Scholar : PubMed/NCBI
17	Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005. View Article : Google Scholar : PubMed/NCBI
18	Jia Y, Zhao LM, Bai HY, Zhang C, Dai SL, Lv HL and Shan BE: The tumor-suppressive function of miR-1296-5p by targeting EGFR and CDK6 in gastric cancer. Biosci Rep. 39:BSR201815562019. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Amaya C, Kurisetty V, Stiles J, Nyakeriga AM, Arumugam A, Lakshmanaswamy R, Botez CE, Mitchell DC and Bryan BA: A genomics approach to identify susceptibilities of breast cancer cells to ‘fever-range’ hyperthermia. BMC Cancer. 14:812014. View Article : Google Scholar : PubMed/NCBI
21	Liu J, Duan Z, Guo W, Zeng L, Wu Y, Chen Y, Tai F, Wang Y, Lin Y, Zhang Q, et al: Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Nat Commun. 9:52002018. View Article : Google Scholar : PubMed/NCBI
22	Narikawa M, Umemura M, Tanaka R, Fujita T, Yokoyama U, Ishigami T, Kimura K, Tamura K and Ishikawa Y: Acute hyperthermia inhibits TGF-β1-induced cardiac fibroblast activation via suppression of Akt signaling. Sci Rep. 8:62772018. View Article : Google Scholar : PubMed/NCBI
23	Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, et al: A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 24:167–181. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hydbring P, Malumbres M and Sicinski P: Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 17:280–292. 2016. View Article : Google Scholar : PubMed/NCBI
25	Tigan AS, Bellutti F, Kollmann K, Tebb G and Sexl V: CDK6-a review of the past and a glimpse into the future: From cell-cycle control to transcriptional regulation. Oncogene. 35:3083–3091. 2016. View Article : Google Scholar : PubMed/NCBI
26	Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, et al: CDK6 antagonizes p53-induced responses during tumorigenesis. Cancer Discov. 8:884–897. 2018. View Article : Google Scholar : PubMed/NCBI
27	Dall'Acqua A, Sonego M, Pellizzari I, Pellarin I, Canzonieri V, D'Andrea S, Benevol S, Sorio R, Giorda G, Califano D, et al: CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med. 9:1415–1433. 2017. View Article : Google Scholar : PubMed/NCBI
28	Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zöchbauer-Müller S, Zuber J, et al: CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 125:90–101. 2015. View Article : Google Scholar : PubMed/NCBI